 
 
 
A PHASE IV, OPEN LAB EL STUDY OF THE EFFE CTS OF 
APREMILAST ON VASCUL AR INFLAMMATION AND 
CARDIOMETABOLIC FUNC TION IN PSORIASIS  
 
 
Principal Investigator:  Joel M. Gelfand MD, MSCE   
University of Pennsyl vania Department of Dermatology  
Perelman Center for Advanced Medicine  
3400 Civic Center Boulevard  
7th Floor, South Tower #730  
Philadelphia, PA 19104  
Phone: 215 -614-0635  
Fax: 215 -615-3127    
Joel.Gelfand@ pennmedicine.upenn.edu  
 
Co-Investigator:  
 Joy Wan MD, MSCE 
University of Pennsylvania Department of Dermatology  
Perelman Center for Advanced Medicine  
3400 Civic Center Boulevard  
7th Floor, South Tower #773  
Philadelphia, PA 19104  
Phone: 215 -615-2937  
Fax: 215 -615-3127     
 joywan@pennmedicine.upenn.edu  
 
Regulatory Sponsor:  Joel M. Gelfand MD, MSCE   
University of Pennsyl vania Department of Dermatology  
Perelman Center for Advanced Medicine  
3400 Civic Center Boulevard  
7th Floor, South Tower #730  
Philadelphia, PA 19104   
Phone: 215 -614-0635  
Fax: 215 -615-3127    
Joel.Gelfand@ pennmedicine.upenn.edu  
 
Funding Source:  Amgen  Corporation  
110 Allen Rd  
Basking Ridge, NJ  07920  
Phone:  908-860-4000  
 
Investigational Product:  
 Apremilast (Otezla)  
Protocol Number:  
 
Amgen  Number:  826652   
 
 
 20207136  
ClinicalTrials.gov Number:                 [STUDY_ID_REMOVED]  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  2 
 
Initial version :  7-21-2016   
 
Amended :    v7.04-03-2017  
 
Amended:       v8.05 -15-2017  
  
Amended :       v9 07 -14-2017  
 
Amended :       v10: 10 -09-17  
 
Amended :   v11: 07 -18-19  
 
Amended : v12: 08 -18-2020  
 
Amended  v13:10.01.2021   
 
Current : v14:12.13 .21 
  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  3 
Table of Contents  
List of Abbreviations  ................................ ................................ ................................ ..........................  6 
Study Summary:  ................................ ................................ ................................ ................................ ... 7 
1. Background and Study Rationale  ................................ ................................ ......................  8 
1.1 Background and Relevant Literature  ................................ ................................ .......................  8 
1.2 Name and Description of the Investigational Product: Apremilast  ............................  9 
1.3 Non-clinical Data  ................................ ................................ ................................ ...............................  9 
1.4 Clinical Data to Date  ................................ ................................ ................................ ........................  9 
1.4.1  Human Pharmacokinetics  ................................ ................................ ................................ .............  9 
1.4.2  Clinical Studies in Adults  ................................ ................................ ................................ ........................  10 
1.4.3  Clinical Studies in Children  ................................ ................................ ................................ ...................  10 
1.5 Dose Rationale  ................................ ................................ ................................ ................................  10 
1.6 Potential Risk  ................................ ................................ ................................ ................................ .. 11 
2 Study Object ives  ................................ ................................ ................................ .........................  11 
2.1 Primary Objectives ................................ ................................ ................................ ........................  11 
2.2 Secondary Objectives  ................................ ................................ ................................ .................  11 
3 Invest igational Plan  ................................ ................................ ................................ ...................  11 
3.1 General Design  ................................ ................................ ................................ ...............................  11 
3.1.1  Screening Phase  ................................ ................................ ................................ ................................ ........  13 
3.1.2  Study Intervention Phase  ................................ ................................ ................................ .......................  13 
3.2 Study Endpoints  ................................ ................................ ................................ ............................  13 
3.2.1  Primary Study Endpoints ................................ ................................ ................................ ........................  13 
3.2.2  Secondary Study Endpoints  ................................ ................................ ................................ .................  13 
3.2.3 Primary Safety Endpoints  ................................ ................................ ................................ ......................  14 
4 Study Population and Duration of Participation ................................ ............................  14 
4.1 Inclusion Criteria  ................................ ................................ ................................ ...........................  14 
4.2 Exclus ion Criteria  ................................ ................................ ................................ ..........................  15 
4.3 Subject Recruitment  ................................ ................................ ................................ .....................  16 
4.4 Duration of Study Participation  ................................ ................................ ...............................  16 
4.5 Total Number of Subjects and Sites  ................................ ................................ ......................  16 
4.6 Vulnerable Populations  ................................ ................................ ................................ ...............  17 
5 Study Drug  ................................ ................................ ................................ ................................ ..... 17 
5.1 Description  ................................ ................................ ................................ ................................ ....... 17 
5.2 Intervention R egimen  ................................ ................................ ................................ ..................  17 
5.3 Receipt  ................................ ................................ ................................ ................................ ...............  17 
5.4 Storage  ................................ ................................ ................................ ................................ ...............  17 
5.5 Preparation and Pa ckaging  ................................ ................................ ................................ ....... 17 
5.6 Administration and Accountability  ................................ ................................ ........................  17 
5.7 Subject Compliance Monitoring  ................................ ................................ ..............................  18 
. 18 
5.8 Return or Destruction of Inv estigational Product  ................................ ...........................  18 
6 Study Procedures  ................................ ................................ ................................ .......................  18 
6.1 Screening (Day -30 to Day -1) ................................ ................................ ................................ ... 18 
6.2 Study Intervention Phase  ................................ ................................ ................................ ...........  18 
6.2.1  Visit 1 / Baseline Visit (Day 0)  ................................ ................................ ................................ .............  18 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  4 
6.2.2  Visit 2 / Week 4 Visit (Day 28 +/ - 7 days)  ................................ ................................ ......................  19 
6.2.3  Visit 3 / Week 8 Visit (Day 56 +/ - 7 days)  ................................ ................................ ......................  19 
6.2.5  Visit 5 / Week 16 Visit (Day 112 +/ - 7 days)  ................................ ................................ .................  19 
6.2.6  Visit 6 / Week 28 Visit (Day 196 +/ - 7 days)  ................................ ................................ .................  20 
6.2.7  Visit 7 / Week 40 Visit (Day 280 +/ - 7 days)  ................................ ................................ .................  20 
6.2.8  Visit 8 / Week 52/EOS Visit (Day 364 +/ - 7 days)  ................................ ................................ ..... 20 
6.3 Unscheduled Visits  ................................ ................................ ................................ .......................  21 
6.4 Subject Withdrawal  ................................ ................................ ................................ .......................  21 
6.5 Early Termination Visits  ................................ ................................ ................................ .............  21 
7 Statistical Plan  ................................ ................................ ................................ .............................  21 
7.1 Primary Endpoint  ................................ ................................ ................................ ...........................  21 
7.2 Secondary Endpoints  ................................ ................................ ................................ ..................  21 
7.3 Sample  Size and Power Determination  ................................ ................................ ................  22 
7.4 Statistical Methods  ................................ ................................ ................................ .......................  22 
7.4.1  Baseline Data  ................................ ................................ ................................ ................................ ...............  22 
7.4.2  Safety A nalysis  ................................ ................................ ................................ ................................ ............  23 
7.5 Subject Population(s) for Analysis  ................................ ................................ ........................  23 
8 Safety and Adverse Events  ................................ ................................ ................................ .... 23 
8.1 Definitions ................................ ................................ ................................ ................................ .........  23 
8.1.1  Adverse Event  ................................ ................................ ................................ ................................ .............  23 
8.1.2  Serious Adverse Event  ................................ ................................ ................................ ............................  23 
8.2 Recording of Adverse Events  ................................ ................................ ................................ .. 24 
8.3 Relationship of AE to Study  ................................ ................................ ................................ ...... 24 
8.4 Reporting of Adverse Events, Adverse Device Effects and Unanticipated 
Problems  ................................ ................................ ................................ ................................ .......................  24 
8.4.1  Follow -up report  ................................ ................................ ................................ ................................ ..........  26 
8.4.2  Investigator reporting: notifying Amgen  ................................ ................................ ..........................  26 
Investigator Reporting: Notifying the Penn IRB  ................................ ................................ ..........  26 
9.1 Stopping Rules  ................................ ................................ ................................ ...............................  27 
9.2 Medical Mo nitoring  ................................ ................................ ................................ .......................  27 
9.2.1  Data and Safety Monitoring Plan  ................................ ................................ ................................ ....... 27 
10 Study Administration, Data Handling and Record Keeping  ................................ . 28 
10.1  Confidentiality  ................................ ................................ ................................ ................................ . 28 
10.2  Data Collection and Management  ................................ ................................ ..........................  28 
10.3  Records Retention  ................................ ................................ ................................ ........................  29 
11 Study M onitoring, Auditing, and Inspecting  ................................ ................................  29 
11.1  Auditing and Inspecting  ................................ ................................ ................................ .............  29 
12 Ethical Considerations  ................................ ................................ ................................ .........  29 
12.1  Risks  ................................ ................................ ................................ ................................ ...................  29 
12.2  Benefits  ................................ ................................ ................................ ................................ ..............  30 
12.3  Risk Benefit Assessment  ................................ ................................ ................................ ...........  30 
12.4  Informed Consent Process / HIPAA Authorization  ................................ .........................  30 
13 Study Finances  ................................ ................................ ................................ ........................  30 
13.1  Funding Source  ................................ ................................ ................................ ..............................  30 
13.2  Conflict of Interest ................................ ................................ ................................ .........................  30 
13.3  Subject Stipends or Payments  ................................ ................................ ................................  30 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  5 
14 Publication Plan  ................................ ................................ ................................ .......................  31 
15 References  ................................ ................................ ................................ ................................ . 31 
16 Attachments  ................................ ................................ ................................ ................................ ..... 35 
16.1  Appendix A - Apremilast Prescribing Information  ................................ ..........................  35 
16.2  Appendix B -  Informed Consent  ................................ ................................ ............................  35 
16.3  Appendix C - Study Flow Chart  ................................ ................................ ...............................  35 
16.4  Appendix D - Dermatology Life Quality Index (DLQI)  ................................ ....................  35 
16.5  Appendix E - Sample Preparation and Handling  ................................ .............................  35 
16.6  Appendix F - Data Safety and Management Plan  ................................ ............................  35 
 
  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  6 
List of Abbreviations  
AE Adverse event  
ALT Alanine transaminase  
AST Aspartate transaminase  
BSA Body surface area  
BUN  Blood urea nitrogen  
cAMP  Cyclic adenosine monophosphate  
CBC  Complete blood count  
Cmax  Maximum serum concentration  
CMP  Complete metabolic profile  
CRF Case report form  
CRP  C-reactive protein  
CYP Cytochrome  
CV Cardiovascular  
DCERN  Dermatology Clinical Effectiveness Research Network  
DICOM  Digital Imaging and Communication in Medicin e 
DLQI  Dermatology Life Quality Index  
ECG  12-lead electrocardiogram  
EC Ethics Committee  
FDA Food and Drug Administration  
FDG  [18F] -fluorodeoxyglucose  
HDL High-density lipoprotein  
Hgb Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act of 1996  
HIV Human immunodeficiency virus  
IDS Investigational Drug Services at the University of Pennsylvania  
IRB Institutional Review Board  
IL Interleukin  
MRHD  Maximum Recommended Human Dose  
NIH National Institutes of Health  
NSAIDs  Non-steroidal anti -inflammatory drugs  
PASI  Psoriasis Area and Severity Index  
PASI -## Reduction of Psoriasis Area and Severity Index by ## (percent ) 
PDE4  Phosphodiesterase -4 
Penn IRB  Institutional Review Board of the University of Pennsylvania  
PET/CT  Positron emission tomography / computed tomography  
PGA  Physician Global Assessment  
PHI Protected health information  
PI Principle Investigator  
SAE Serious adverse event  
SD Standard deviation  
SUV Standard uptake value  
TAB Total atherosclerosis burden  
TB Tuberculosis  
TBR Tissue -to-background ratio  
Th1 T helper cell type 1  
Th17  T helper cell type 17  
Tmax  Time to reach maximum concentration  
TNF Tumor necrosis factor  
VAS Visual analog scale  
WBC  White blood cell  
 
  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  7 
Study Summary : 
 
Title A Phase IV, Open label Study of the Effects of Apremilast on Vascular 
Inflammation and Cardiometabolic function in Psoriasis  
Short Title  Vasc ular Inflammation in Psoriasis -Apremilast (VIP -A) 
IRB Number  826652  
Protocol Number  97509210  
Phase  Phase IV  
Methodology  Single arm, open label, self -controlled trial  
Study Duration  Up to 30 day screening period, treatment period of 52  weeks per subject  
Study Center(s)  Multicenter within the Dermatology Clinical Effectiveness Research Network 
(DCERN). The lead site and coordinating center is the University of 
Pennsylvania.  
Objectives  The primary objectives of this study are to determine the effect of apremilast 
on aortic vascular inflammation , cardiometabolic biomarkers  and body 
composition  in patients with moderate -severe psoriasis. FDG -PET/CT will be 
used to assess v ascular inflammation , with multi -volumetric product, tissue -
to-background ratio and total atherosclerotic burden , and body composition 
via volumetric quantification.  
Number of Subjects  70 patients 
Main Inclusion and 
Exclusion Criteria  Males and females 18 years of age and older with moderate to severe plaque 
psoriasis defined by ≥10% Body Surface Area affected and Psoriasis Area 
and Severity Index ≥12. Subjects must be candidates for systemic therapy 
and have active psoriasis despite treatment with topical agents.  
Study Product:  
 Apremilast  tablets, oral  
Day 1: 10 mg in AM  
Day 2: 10 mg AM and PM  
Day 3: 10 mg AM and 20 mg PM  
Day 4: 20 mg AM and PM  
Day 5: 20 mg AM and 30 mg PM  
Day 6: 30 mg PO BID  
Day 7 -week 52: 30 mg PO BID  
Duration of 
administration  52 weeks  
Reference therapy  Not applicable  
Endpoints  The primary endpoints to be measured in this study include: c hange from 
baseline  in total vascular inflammation of the aorta , as assessed on FDG -
PET/CT , and change in c ardiometabolic  biomarkers  at week 16.   
 
The secondary endpoints to be measured are change in  vascular 
inflammation between week 52 and earlier time points , change from baseline 
in cardiometabolic biomarkers at other time points (week 4, 8, 12 , 52), 
volumetric changes in visceral and subcutaneous adipose tissue, changes in 
physician reported outcomes (PASI, PGA), changes in patient reported 
outcomes (DLQI , pruritus VAS ) and safety endpoints.    
Statistical 
Methodology  Descriptive statistics, Wilcoxon signed rank  tests, multivariable linear 
regression, and exploratory analyses will be conducted  
Safety Evaluations   Monitoring for a dverse events and serious adverse events  
 Vital signs, physical examination  
 Laboratory assessments (e.g., hematology, chemistry)   
 
  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  8 
1. BACKGROUND AND STUDY  RATIONALE  
1.1 Background and Relevant Literature  
Psoriasis is a common T -helper cell type 1 (Th1) and type 17 (Th17) mediated inflammatory disease, 
affecting 2 -3% of the population.1-3 Over 7.5 million Americans have been diagnosed  with psoriasis and 
about 1 million have moderate to severe disease requiring systemic treatments.4 Despite the broad array 
of therapeutic options, about 70% of patients with severe psoriasis affecting ≥10% body surface area (BSA) 
are not receiving treatment to control their disease.5 It is now increasingly recognized that psoriasis, like 
rheumatoid arthritis and systemic lupus erythematosus, is a systemic inflammatory disorder and not only a 
disorder limited to the skin.6 In support of this, increasing evidence identifies psoriasis, particularly severe 
disease, as an independent risk factor for diabetes mellitus, dyslipidemia, myocardial infarction, stroke, and 
cardiovascular (CV) mortality.7-20 
 
The pathoph ysiology of psoriasis is characterized by inflammation with increased antigen presentation and 
lymphocyte activity and up -regulation of Th1/Th17 cytokines. Serum levels of inflammatory markers, 
including C -reactive protein (CRP) and tumor necrosis factor ( TNF) -α, interleukin (IL) -6, IL-18, IL -12, IL -17 
and IL -22 are chronically increased in patients with psoriasis and correlate with psoriasis severity.21-27 
Elevated levels of  cytokines including IL -6 and TNF -α, cell adhesion molecules, and downstream acute -
phase reactants such as CRP and fibrinogen have been associated with increased cardiovascular 
risk.14,17,28-35 The role of Th17 cells in atherogenesis remains less clear, however, with evidence sugges ting 
both pro - and anti -atherogenic effects.36,37 It is evident, however, that, in general, systemic inflammation in 
psoriasis shares similar pathophysiology with atherosclerotic cardiovascular disease.6,38-40 
 
A preliminary study on experimentally induced in vivo inflammation revealed that robust activation of TNF -
α and IL -6 is foll owed by a systemic insulin -resistant state, metabolic dyslipidemia and decreased high -
density lipoprotein (HDL) function.41 Dysfunction of three inter -related pathways have been shown in 
patients with psoriasis: 1) Pro -atherogenic lipoprotein profiles (reduced HDL, elevated triglycerides, and 
increased small dense low -densit y lipoprotein particles),42,43 2) impaired macrophage cholesterol efflux and 
reverse cholesterol transport,44,45 and 3) inflammation -induced adipose and metabolic dysfunction (increase 
in leptin and insulin, and decrease in adiponectin).41,46 These data suggested potential biologic links to 
vascular inflammation and accelerated CV disease development.  
 
An in novative method to investigate the systemic inflammatory burden of psoriasis is with [18F] -
fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT). FDG -PET/CT 
is a validated imaging technique that enables highly sensitive and p recise measurements of inflammation 
in vivo .47 FDG uptake in arterial walls reflects metabolic activity of inflammatory cells, particularly 
macrophages, within atherosclerotic lesions.48 In a pilot study , it was observed that psoriasis is associated 
not only with clinically observed inflammation in the skin, but also foci of subclinical inflammation within the 
liver, joints, tendons, and aorta that were not explained by traditional cardiovascular risk fac tors or co -
morbidities.49 Moreover, increasing severity of skin disease in psoriasis is associated with increasing 
severity of aortic vascular inflammation50. Since vascular inflammation on FDG -PET/CT strongly predicts 
future major vascular events and is responsive to even short term interventions for traditional CV risk 
factors,  51-55 it may also serve as a useful marker for evaluating vascular inflammation an d, thus, 
cardiovascular risk in response to psoriasis treatments.  
 
Cyclic adenosine monophosphate  (cAMP) is a key modulator of immune cell responses and is 
predominantly regulated by phosphodiesterase 4 (PDE4). Apremilast is  an oral  selective PDE4  inhibito r 
that is FDA approved for the treatment of psoriasis (see section 1.2) . PDE4 inhibition down -regulates  the 
inflammatory response by reducing the expression of tumor necrosis factor (TNF) -α, interleukin (IL) -23, and 
other pro -inflammatory cytokines, while increasing anti -inflammatory cytokines, such as IL -1056,57.  cAMP 
also plays an important role in regul ation of macrophage inflammatory responses , and PDE4 inhibition has 
been shown to dramatically decrease the inflammatory response of macrophages58. 
 
Macrophages play an im portant role  in the pathogenesis of atherosclerosis, contributing at all stages59. 
Macrophages ingest lipoproteins, transforming them into cholesterol -laden foam cells. T hese foam cells 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  9 
persist in plaques and promote disease progression60. They represent a major component of vessel wall 
inflammation. Macrophages also recruit additional i nflammatory cytokines and play a role in ather osclerotic 
plaque destabilization61. We, therefore, propose this open -label clinical trial to investigate the effect s of 
apremilast , an oral PDE4 inhibitor,  on aortic vascular inflammation , as measured by FDG -PET/CT imaging  
and cardiometabolic biomarkers in patients  with moderate to severe psoriasis.  In addition, metabolic 
syndrome and obesity are highly prevalent in psoriasis and it is therefore of special interest that in the phase 
III clinical trials for  apremilast, 20.2% of patients had weight loss, not associated with gastrointestinal side 
effects62. Because of this, the above CT imaging will also be used to measure changes in abdominal fat 
composition in patients taking apremilast.  
1.2 Name and Description  of the Investigational Product : Apremilast   
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor. Apremilast is known chemically as N -[2-[(1S) -1-(3-
ethoxy -4-methoxyphenyl) -2-(methylsulfonyl)ethyl] -2,3-dihydro -1,3-dioxo -1H-isoindol -4-yl]acetamide. Its 
empi rical formula is C22H24N2O7S and the molecular weight is 460.5  g/mol . Each tablet contains 
apremilast as the active ingredient and the following inactive ingredients: lactose monohydrate, 
microcrystalline cellulose, croscarmellose sodium, magnesium. Apremilast is an oral small -molecule 
inhibitor of PDE4  specific for cyclic  adenosine monophosphate (cAMP). PDE4 inhibition results in 
increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic 
action in psoriatic arthritis patients and psoriasis patients is not well defined . 
1.3 Non-clinical Data  
Long -term studies were cond ucted in mice and rats with apremilast to evaluate its carcinogenic potential. 
No evidence of apremilast -induced tumors was observed in mice at oral doses up to 8.8 -times the 
Maxim um Recommended Human Dose (MRHD)  on an  AUC basis (1000 mg/kg/day) or in rats at oral 
doses up to approximately 0.08 - and 1.1 -times the MRHD, (20 mg/kg/day in males and 3 mg/kg/day in 
females, respectively).  
 
Apremilast tested negative in the Ames assay, in vitro chromosome aberration assay of human peripheral 
blood lymphocytes, and the in vivo mouse micronucleus assay .  
 
In a fertility study of male mice, apremilast at oral doses up to approximately 3 -times the MRHD based on 
AUC (up to 50 mg/kg/day) produced no effects on male fertility. In a f ertility study of female mice, 
apremilast was administered at oral doses of 10, 20, 40, or 80 mg/kg/day. At doses ≥1.8 -times the MRHD 
(≥20 mg/kg/day), estrous cycles were prolonged, due to lengthening of diestrus which resulted in a longer 
interval until m ating. Mice that became pregnant at doses of 20 mg/kg/day and greater also had 
increased incidences of early post -implantation losses. There was no effect of apremilast approximately 
1.3-times the MRHD (10 mg/kg/day) .  
1.4 Clinical Data to Date  
1.4.1  Human Pharmacokinetics  
Absorption:  Apremilast , when taken orally , is absorbed with an absolute bioavailability of ~73%, with 
peak plasma concentrations (Cmax) occurring at a median time (tmax) of ~2.5 hours. Co -administration 
with food does not alter the extent of absorption of apremilast.  
 
Distribution:  Human plasma protein binding of apremilast is approximately 68%. Mean appa rent volume 
of distribution  is 87 L.  
 
Metabolism : Following oral administration in humans, apremilast is a major circulating component (45%) 
followed by inactive metabolite M12 (39%), a glucuronide conjugate of O -demethylated apremilast. It is 
extensively metabolized in humans with up to 23 metabolites identified in plasma, urine and feces. 
Apremilast is metabolized by both cytochrome (CYP) oxidative metabolism with subsequent 
glucuronidation and non -CYP mediated hydrolysis. In vitro, CYP metabolism of apremilast is primarily 
mediated by CYP3A4, with min or contributions from CYP1A2 and CYP2A6.  
 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  10 
Elimination : The plasma clearance of apremilast is about 10 L/hr in healthy subjects, with a terminal 
elimination half -life of approximately 6 -9 hours. Following oral administration of radio -labeled apremilast, 
about 58% and 39% of the radioactivity is recovered in urine and feces, respectively, with about 3% and 
7% of the radioactive dose recovered as apremilast in urine and feces, respectively . 
1.4.2  Clinical Studies in Adults  
Two multicenter, randomized, double -blind, placebo -controlled trials (Studies PSOR -1 and PSOR -2) 
enrolled a total of 1257 subjects 18 years of age and older with moderate to severe plaque psoriasis 
[body surface area (BSA) involvement of ≥10%, Physician Gl obal Assessment (PGA) of ≥3 (moderate or 
severe disease), Psoriasis Area and Severity Index (PASI) score ≥12, candidates for phototherapy or 
systemic therapy]. Subjects were allowed to use low -potency topical corticosteroids on the face, axilla 
and groin. Subjects with scalp psoriasis were allowed to use coal tar shampoo and/or salicylic acid scalp 
preparations on scalp lesions.  
 
Study PSOR -1 enrolled 844 subjects and Study PSOR -2 enrolled 413 subjects. In both studies, subjects 
were randomized 2:1 to apre milast 30 mg BID or placebo for 16 weeks. Both studies assessed the 
proportion of subjects who achieved PASI -75 at Week 16 and the proportion of subjects who achieved a 
PGA score of clear (0) or almost clear (1) at Week 16. Across both studies, subjects ra nged in age from 
18 to 83 years, with an overall median age of 46 years. The mean baseline BSA involvement was 25.19% 
(median 21.0%), the mean baseline PASI score was 19.07 (median 16.80), and the proportion of subjects 
with PGA score of 3 (moderate) and 4  (severe) at baseline were 70.0% and 29.8%, respectively. 
Approximately 30% of all subjects had received prior phototherapy and 54% had received prior 
conventional systemic and/or biologic therapy for the treatment of psoriasis with 37% receiving prior 
conventional systemic therapy and 30% receiving prior biologic therapy. Approximately one -third of 
subjects had not received prior phototherapy, conventional systemic nor biologic therapy. A total of 18% 
of subjects had a history of psoriatic arthritis.  
 
The proportion of subjects who achieved PASI -75 responses, and PGA score of clear (0) or almost clear 
(1), are presented in Table 1.  The median time to loss of PASI -75 response among the subjects re -
randomized to placebo at Week 32 during the Randomized Trea tment Withdrawal Phase was 5.1 weeks  
 
Table 1: Clinical Response at Week 16 in Studies PSOR -1 and PSOR -2 
 Study PSOR -1 Study PSOR -2 
 Placebo  apremilast  
30mg BID  Placebo  apremilast  
30mg BID  
 N = 282  N = 562  N = 137  N = 274  
PASI -75, n (%)  15 (5.3)  186 (33.1)  8 (5.8)  79 (28.8)  
PGA of Clear of Almost Clear, n 
(%) 11 (3.9)  122 (21.7)  6 (4.4)  56 (20.4)  
1.4.3  Clinical Studies in Children  
The safety and effectiveness of apremilast  in pediatric patients less than  18 years of age have not been 
established . 
1.5 Dose Rational e  
Apremilast is given with an initial dosage titration for the first five days (see Table 2) and then 30mg twice 
daily therefore after. This is the FDA -approved dose regimen for treatment of moderate to severe plaque 
psoriasis.  
 
Table 2: Apremilast Dosage Titration Schedule  
Day 1  Day 2  Day 3  Day4  Day 5  Day 6 & 
thereafter  
AM AM PM AM PM AM PM AM PM AM PM 
10mg  10mg  10mg  10mg  20mg  20mg  20mg  20mg  30mg  30mg  30mg  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  11 
1.6 Potential Risk  
  
 
The following side effects may be associated with the use of apremilast:  
 Very common: diarrhea, nausea (stomach upset),  
 Common: upper abdominal (stomach) pain,  vomiting  indigestion , frequent bowel movement s, 
heartburn , fatigue , bronchitis (infection of the tubes to the lungs), redness /swelling/pain in the 
sinuses, inflammation or infections of the nose and throat , upper respiratory tract infection,  
decreased appetite, back pain, headache (including tension and migraine), difficulty sleeping, 
depression , cough ,   
 Uncommon: allergic reaction ,  weight loss,  rash 
 
Pregn ancy Risks : Apremilast is pregnancy category C.  Category C means that animal studies have 
revealed adverse fetal effects but that no controlled studies in women have been done, or that no studies 
in women or animals are available.  
2 Study Objectives  
2.1 Primary Objective s 
To assess the effects of apremilast, in patient s with moderate to severe psoria sis on:  
 Vascular inflammation as measured by FDG -PET/CT  
Cardiometabolic biomarkers : lipid particle size, HDL function (cholesterol efflux), TNF -Alpha, IL -6, C 
reactive protein, leptin, adiponectin, insulin levels  and glucose to yield HOMA -IR, apolipoprotein B, 
ferritin, interleukin -2 receptor A, , fetuin -A, GlycA,ICAM -1, Serum amyloid A,  VCAM -1,  IFN -g,IL-1b, ,IL-
17A,IL -8, MCP -1, IL-9, IL-10, beta hydroxybuty rate, acetoacetic acid, Acetone, Ketone bodies,  TRLTG, 
TRLC, TRLP, VL_TRLP,  L_TRLP, M_TRLP, S_TRLP,  VS_TRLP, Valine, Leucine, Isoleucine, 
BCAA,  Alanine , ApoA1,Citrate and Diabetes Risk Index.  
  
             
 
 
   
2.2 Secondary Objectives  
To assess the effects of apremilast, in patient s with moderate to severe psoriasis on:  
 Body composition , as measured by FD G-PET/CT  
 Psoriasis activity and severity  
 Pruritus, as measured by a VAS  
 Patient reported quality of life ( DLQI ) 
 Safety  
 
3 Investigational Plan   
3.1 General Design  
This study is a phase IV, open -label 52-week clinical trial to investigate the efficacy of apremilast in 
reducing vascular inflammation and cardiometabolic risk biomarkers in patients with moderate to severe 
psoriasis. The subject inclusion and exclusion criteria are shown in Sections 4.1 and 4 .2. This will be a 
multicenter trial with a goal enrollment of 70 patients.  Subjects will receive apremilast for a total of 52 
weeks at the FDA approved dose for moderate -severe psoriasis . 
 
All study procedures , including screening, will occur only after obtaining signed informed consent.  During 
the screening period, baseline, weeks 4, 8, 12 , 16, 28, 40 and 52  subjects will be evaluated by 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  12 
investigators  or designated research personnel . Psoriasis severity will be assessed using the Psoriasis 
Area and Sever ity Index (PASI) and the Physician Global Assessment (PGA), both widely accepted 
measurement tools for psoriasis63.  The Dermatology Life Quality Index (DLQI) will also be measured to 
collect informa tion regarding patient -oriented outcomes64, 65. 
 
FDG -PET/CT will be conducted at baseline , week 16  and week 52 . Subjects will undergo a FDG -PET/CT 
scan using the standard protocol as described below.   Subjects will be required to fast for 8 hours prior to 
the scan. At the imagin g center, finger -stick ser um glucose levels will be checked to ensure a glucose 
level <150 mg/dL prior to FDG administration. If the glucose level exceeds 150 mg/dL, consultation with 
the principal investigator prior to the imaging will be required to determine if the subject is el igible to 
continue in the study. Neck to iliac crests  PET/CT image acquisition will begin about 120 minutes (± 10 
minutes) after IV administration of 15 mCi of [18F] -FDG  or other appropriate weight -based dose per 
imaging site’s standard dosing protocol . Axial, sagittal, and coronal PET reconstructions will be 
interpreted with and without attenuation correction, using non -contrast CT images for anatomical 
correlation. Within approximately 24 hours after the completion of the FDG -PET/CT scan, the local 
nuclear medicine personnel will issue a clinical report determining if the subject has any clinically 
significant findings which could preclude the subject’s continued participation in the study.  
 
The arterial uptake of FDG will be measured by the maximum standardized uptake value (SUV) divided 
by the venous SUV mean , a previously reported method for quantifying vascular inflammation65. This will 
yield a maximum target to background ratio (TBR max) which is considered the standard reporting variable 
in FDG -PET/CT vascular studies66. The PET/CT images obtained from each site’s local imaging center 
will be de -identified and sent to the University of Pennsylvania Imaging Lab where trained nuclear 
medicine personnel will undertake a qualitative review of the PET/C T images. During this review, two -
dimensional (2D) circular regions of interests (ROIs) will be manually placed on the PET images around 
the external aortic contour, around the hepatic margin, and around articular spaces on all transverse 
slices passing th rough these structures using low -dose CT images for anatomic guidance. The images 
will then be sent to the central core National Institutes of Health (NIH) Imaging Lab for measuring the 
SUVs. The NIH central PET/CT readers will be blinded to time  point of scan  via Digital Imaging and 
Communication in Medicine (DICOM) file editing applied by the University of Pennsylvania.  
 
In addition to the mean SUV of the whole aorta, mean SUV s will be calculated for five segments of the 
aorta: ascending aorta, aortic arc h, descending thoracic aorta, suprarenal abdominal aorta, and infrarenal 
abdominal aorta. These segments are defined to consider separately various regions of aortic disease 
that are associated with different clinical phenotypes (e.g., aortic arch disease with stroke, abdominal 
aortic disease with abdominal aortic aneurysm)  48,49,6 6,67,68. 
 
Adipose tissue volumes will be  assessed at L2 –L3 using automated  software , as has been previously 
reported69. The algorithm will consist  of body masking, noise  reduction, adipose tissue labeling, viscera l 
adipose tissue ( VAT) and subcu taneous adipose tissue  (SAT) separation,  and quantitation. The adipose 
tissue volume  inside the internal contour contributes to the VAT and  the adipose tissue volume between 
the external contour and  internal contour contributes to SAT.  
 
Laboratory tests will be conducted at screening, baseline and weeks 4, 8, 12 , 16 and 52 . This includes 
labs for screening safety and cardiometabolic biomarkers . Blood will be coll ected as described in 
Appendix E. In summary, a  total volume of 30 mL (34.5 mL for Penn participants at Week 0 and Week 16 
only)  will be drawn per patient. Tubes will be labeled with an ID that does not contain identifiable 
personal information. The date and time of sample collection will be also indicated on a lab transfer sheet. 
Tubes will be sent directly to a lab at the NIH where the samples will be processed and stored.  
 
The blood will be used for making aliquots of plasma and serum for storage at -80° C after centrifugation 
of sample s for 20 minutes at 2,400 RPM.  Any remaining plasma and/or serum will be destroyed at the 
completion of the study , except as required for quality  assurance .  All samples are run in duplicate and 
normalized to a control pooled sample run simultaneously.  
 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  13 
The expected duration of this open -label trial for each participant is 52 weeks, in addition, to an initial 
screening visit and screening period of up to 30 days. 
3.1.1  Screening Phase  
Before subjects may be screened for enrollment into this study, full IRB approval of the protocol and 
consent will be obtained. Subjects will be provided with the approved informed consent form and 
complete the informed consent process according to FDA regulations and Good Clinical P ractice  
guidelines prior to any study related procedures.  Upon signing consent, subjects will be screened to 
determine their eligibility for the study (see sections 4.1 and 4.2).   
 
Subjects who meet the inclusion and exclusion criteria will undergo a screening assessment within 30 
days of study enrollment. This includes a complete medical history and physical exam; vital signs and 
weight; routine blood work ( CBC, CMP) , HIV, hepatitis  B surface antigen , hepatitis C antibodies, and  
urine  pregnancy test . Details of the screening procedures can be found in Section 6.2. If a subject reports 
current use of a psoriasis therapy at time of screening assessment, the study physician will determi ne, 
based on psoriasis severity and overall medical history, whether the subject can undergo a washout 
period.  The subject will then be informed of what to expect during a washout period and will be asked to 
decide whether they would like to continue with  the study.  If the subject decides to continue, he/she will 
be monitored for AEs during the washout period and routine blood work will be repeated for subjects who 
complete a washout period of greater than 30 days.  Subjects who complete all screening vis it 
procedures and meet the inclusion and exclusion criteria will undergo baseline FDG -PET/CT and 
cardiometabolic assessments. If screening assessment exceeds 30 days, the study PI should be 
consulted for guidance on determining whether all screening proced ures should be repeated or findings 
are considered clinically stable and subject can continue with baseline visit procedures.   
 
Administrati on of the initial dose of study treatment (apremilast ) must occur 7 days or less from date of 
FDG -PET/CT scan . If initial dose cannot occur within 7 days of FDG -PET/CT scan, the study PI should 
be consulted for guidance on course of treatment.     
3.1.2  Study Intervention Phase  
All patients will receive apremilast at the FDA-approved dose for plaque psoriasis for a tot al of 52 weeks.  
At weeks 4, 8, 12 , 16, 28, 40 and 52 , subjects will be evaluated by investigators  or designated research 
personnel . Psoriasis severity will be assessed using the Psoriasis Area and Severity Index (PASI) and the 
Physician Global Assessment (PGA).  Laboratory tests will also be conducted at baseline  and weeks 4, 8, 
12, 16, and 52  for screening safety labs and/or cardiomet abolic biomarker assessment.  FDG -PET/CT will 
be conducted at baseline , week 16  and week 52 . 
3.2 Study  Endpoints  
3.2.1  Primary Study Endpoints  
The primary endpoints to be measured in this study include:  
 Change in total vascular inflammation of the whole aorta as assessed on FDG -PET/CT between 
baseline and week 16  
 Change in cardiometabolic biomarkers  (lipid particle size, HDL function (cholesterol efflux), TNF -
Alpha, IL -6, high s ensitivity C reactive protein, leptin, adiponectin, insulin levels  and glucose to 
yield HOMA -IR, apolipoprotein B, ferritin, interleukin -2 receptor A, interleukin -18, and fetuin -A) 
between baseline and week 16  
3.2.2  Secondary Study Endpoints  
The secondary endpoints to be measured in this study include:  
 Change in total vascular inflammation of the five aortic segments  as assessed on FDG -PET/ CT 
between baseline and week 16, and between baseline and week 52   
 Change in cardiometabolic  biomarkers at week 4, 8, 12 , 16 and 52 compared to baseline and 
earlier time points  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  14 
 Change in total vascular inflammation of the aorta as assessed on FDG -PET/CT between week 
52 and earlier time points  (basel ine and week 16)  
 Changes in body composition as measured on FDG -PET/CT  between week 52 and earlier time 
points (baseline and week 16)  
 Changes in physician reported outcomes (PASI , PGA ) 
 Changes in the patient reported outcomes  (DLQI , pruritus VAS ) 
 Safety endpoints  
3.2.3  Primary Safety Endpoints  
The safety endpoint s will be assessed by subject interview (and physical exam , if indicated) as well as 
blood laboratory examination. Subjects will be monitored for any adverse event t hat occur during the 
study including serious adverse events (e.g., serious infection and malignancy ). Non-serious adverse 
events, as defined in Section 8.1, will also be noted. A complete review of systems will also be assessed 
and physical exam performed at baseline and week 16.  The followi ng routine laboratory tests will be 
monitored as safety parameters and will be drawn during screening and at week s16 and 52 .    
 Hematology:  complete blood count (CBC) with differential  
 Complete metabolic profile: sodium, potassium, chloride, bicarbonate, blood urea nitrogen, 
creatinine, glucose , aspartate aminotrans ferase , alanine aminotransferase , alkaline phosphatase, 
total and direct bilirubin, total protein, albumin   
4 Study Population and Duration of Participation   
4.1 Inclusion Criteria  
1) Males and females 18 years of age and older.  
2) Clinical diagnosis of psoriasis for at least 6 months as determined by subject interview of his/her 
medical history and confirmation of diagnosis through physical examination by Investigator.  
3) Stable plaque psoriasis for at least 2 months before screening and at baseline (Week 0) as 
determined by subject interview of his/her medical history.  
4) Moderate to severe psoriasis defined by ≥ 10 percent Body Surface Area (BSA) involvement at the 
baseline (Week 0) visit.  
5) PASI score of ≥ 12 at  the Baseline (Week 0) visit.  
6) Subject is a candidate for systemic therapy and has active psoriasis despite prior treatment with 
topical agents.  
7) Women are eligible to participate in the study if they meet one of the following criteria:  
a) Females of  childbeari ng potential (FCBP) must have a negative pregnancy test at screening and 
baseline. Women of childbearing potential must undergo periodic pregnancy testing during the 
study and agree to use at least one of the following methods of contraception throughout t he 
study duration  and for at least 28 days after taking the last dose of investigational product : 
i) Oral contraceptives  
ii) Transdermal contraceptives  
iii) Injectable or implantable methods  
iv) Intrauterine devices  
v) Vaginal ring  
vi) Vasectomized partner  
vii) Barrier methods Male or female condom  PLUS one additional barrier method: (a) diaphragm 
with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with 
spermicide. );  
b) Women who are postmenopausal (for at least one year), sterile, or hysterectomized;  
c) Women who have undergone tubal ligation will be required to undergo periodic pregnancy testing 
during the duration of the study  
d) Sexual abstinence, defined as total abstinence from sexual intercourse, is considered an 
adequate form of contraception.  (Agree ment to comply with sexual abstinence must be recorded 
in the source document ). 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  15 
e) Subjects using oral or parenteral  forms of contraceptives must have been using these methods  
for at least 90 days  prior to baseline visit . 
 
8).Subject is judged to be in good general health as determined by the Principal Investigator based upon 
the results of medical history, laboratory profile  and physical examination performed at screening.  
4.2 Exclusion Criteria  
Subjects meeting any of the following criteria will be excluded from the study:  
1. Prior treatment with apremilast  is permissible under the following conditions:  
a. Prior exposure did not result in a clinical outcome such as side effect or lack of efficacy 
that would contraindicate future treatment with apremilast  
b. For patien ts who have only taken the apremilast two week starter pack  (defined as 13-
tablet blister titration pack containing: (4) 10 -mg, (4) 20 -mg, and (5) 30 -mg tablets with an 
additional (14) 30 -mg tablets ), apremilast must be discontinued at least 30 days prior to 
baseline (week 0)  
c. For patients with apremilast exposure greater than one two week starter pack, apremilast 
must be discontinued at least 90 days prior to baseline (week 0) .  
2. Diagnosis of erythrodermic psoriasis, generalized or localized pustular psorias is, medication -
induced or medication -exacerbated psoriasis, or new onset guttate psoriasis.  
3. Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may 
interfere with evaluation of psoriasis.  
4. Cannot avoid topical prescription medications for psoriasis for at least 14 days prior to the 
baseline visit (week 0) and during the study , with the exception of hydrocortisone 2.5% for the 
face and intertriginous areas . 
5. Cannot avoid UVB phototherapy or Excimer laser for at le ast 14 days prior to the Baseline (Week 
0) visit and during the study.  
6. Cannot avoid psoralen -UVA phototherapy for at least 30 days prior to the Baseline (Week 0) visit 
and during the study.  
7. Use of systemic therapies for the treatment of psoriasis, or syste mic therapies known to improve 
psoriasis, during the study:  
a. Systemic therapies must be discontinued at least 30 days prior to the Baseline (Week 0) 
visit except for biologics  and apremilast exposure greater than one two week starter 
pack . 
b. All biologics, ex cept IL -12/IL -23 antagonists, must be discontinued for at least 90 days 
prior to Baseline (Week 0).  
c. Any IL -12/IL -23 antagonist (e.g., ustekinumab, briakinumab) must be discontinued for at 
least 180 days prior to Baseline (Week 0).  
d. Investigational agents m ust be discontinued at least 30 days or 5 half -lives (whichever is 
longer) prior to the Baseline (Week 0) visit.  
8. Subject is ≥ 300lbs  (136.1 kg) at Baseline (Week 0).  
9. Subject is taking or requires oral or injectable corticosteroids during the study. Inhale d 
corticosteroids for stable medical conditions are allowed.   
10. Subject is taking a medication that interferes with metabolism  of apremilast, including but not 
limited to rifampin, phenobarbital, carbamazepine , phenytoin  
11. Poorly controlled medical condition,  such as unstable ischemic heart disease, cerebrovascular 
accident or myocardial infarction within the prior 6 months, psychiatric disease requiring frequent 
hospitalization, and any other condition, which, in the opinion of the Investigator, would put the  
subject at risk by participation in the study.  
12. Prior history of suicide attempt at any time in the subject’s life time prior to screening or 
randomization, or major psychiatric illness requiring hospitalization within the last 3 years.  
13. Uncontrolled hypert ension, with measured systolic blood pressure >180 mmHg or diastolic blood 
pressure > 95 mmHg  
14. Subject has infection or risk factors for severe infections, for example  
a. Positive serology or known history of HIV, hepatitis B or C, or other severe, recurrent, o r 
persistent infections;  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  16 
b. Excessive immunosuppression or other factors associated with it, including human 
immunodeficiency virus infection;  
c. Active tuberculosis (TB) disease;  
d. Any other significant infection requiring hospitalization or intravenous (IV) anti biotics in 
the 30 days prior to baseline ; 
e. Infection requiring treatment with oral or parenteral (other than IV) antibiotics within 14 
days prior to baseline ; 
f. Subject has received vacc ination with a live viral agent within 30 days prior to screening 
or will  require a live vaccination during study participation including up to 30 days after 
the last dose of study drug.  
15. Subject has history of hematological or solid malignancy other than successfully treated basal cell 
carcinoma, non -metastatic cutaneous squamo us cell carcinoma or cervical intraepithelial 
neoplasia or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 
years.  
16. Female subject who is pregnant or breast -feeding or considering becoming pregnant during the 
study.  
17. Screening  clinical laboratory analyses showing any of the following abnormal results:  
a. White blood cell (WBC) count < 3.0 x 109/L. (Subject can be included if WBC count is < 3.0 
x 109/L and absolute neutrophil count (ANC) is >1000 cells / mm3.) 
b. WBC count > 15 x 109/L; 
c. Hemoglobin (Hgb) < 9.0 x 109/L; 
d. Platelet count < 100 x 109/L; 
e. Serum creatinine >1. 5 mg/dL ;  
f. Serum aspartate transaminase or alanine transaminase > 2.0 upper limits of normal  
18. Recent history of substance abuse , within 365 days of Baseline (Week 0) visit that could preclude 
compliance with the protocol.  
19. Alcohol use of more than 14 drinks per week within 14 days of the baseline visit   
20. If subject is on cholesterol -lowering medication (e.g. statin), dose and form of medication must be 
stable for 90 days prior  to week 0 and remain stable throughout the duration of the study . 
4.3 Subject Recruitment  
This study is a multicenter clinical trial with subjects recruited from clinical practices within the 
Dermatology Clinical Effectiveness Research Network  (DCERN) . At th e primary site, the Principal 
Investigator has extensive experience in clinical research in psoriasis, and the University of Pennsylvania 
is a referral center for patients with psoriasis.  All recruitment materials will be submitted to the 
Institutional Re view Board (IRB) of the University of Pennsylvania and receive written approval prior to 
their use.  
  
Before subjects may be screened for enrollment into this study, full IRB approval of the protocol and 
consent will be obtained. Subjects will be provided  with the approved informed consent form and 
complete the informed consent process according to FDA regulations and Good Clinical P ractice  
guidelines prior to any study related procedures.  Upon signing consent, subjects will be screened to 
determine their  eligibility for the study (see sections 4.1 and 4.2) . 
 
Subjects who meet the inclusion and exclusion criteria will undergo a screening assessment within 30 
 days  of study enrollment. Details of the screening procedures can be found in Section 6.2. Subjects who 
complete all screening visit procedures , and meet the inclusion and exclusion criteria , will undergo 
baseline FDG -PET/CT and cardiometabolic biomarker asses sments.  
4.4 Duration of Study Participation  
The duration of study participation will be 52 weeks . 
4.5 Total Number of Subjects and Sites  
Recruitment will end when 70 subje cts are enrolled.  It is expected that 70 subjects will be enrolled in 
order to produce about 35 evaluable subjects, assuming a dropout rate at week 52 of 50%.  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  17 
4.6 Vulnerable Populations  
Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study.  
5 Study Drug   
5.1 Description  
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor. Apremilast is known chemically as N -[2-[(1S) -1-(3-
ethoxy -4-methoxyphenyl) -2-(methylsulfonyl)ethyl] -2,3-dihydro -1,3-dioxo -1H-isoindol -4-yl]acetamide. Its 
empirical formula is C22H24N2O7S and the molecula r weight is 460.5.  Tablets are supplied in 10 -, 20-, 
and 30 -mg strengths for oral administration. Each tablet contains apremilast as the active ingredient and 
the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose 
sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red, 
iron oxide yellow (20 and 30 mg only) and iron oxide black (30 mg only).  
5.2 Intervention Regimen  
See section 1.3  
5.3 Receipt  
Apremilast is an FDA -approved drug manufactured by Amgen  Corporation.  It will be provided by Amgen  
Corporation, and delivered to the attention of Kenneth Rockwell, PharmD to the following address:  
 
 University of Pennsylvania  Investigational Drug Service  (Penn IDS)  
 Ground Floor Maloney Building  
 3600 Spruce Street  
 Philadelphia, PA 19104  
 (215) 349 -8817  
 
Upon receipt of the of the study treatment supplies, an inventory must be performed and a drug receipt 
log filled out and signed by the person accepting the shipment. It is important that the designated study 
staff counts and verifies that the shipment contains all the items noted in the shipment inventory. Any 
damaged or unusable study drug in a given shipment will be documented in the study files. The 
investigator mus t notify Amgen  Corporation, of any damaged or unusable study treatments that were 
supplied to the investigator’s site .  
5.4 Storage  
Apremilast should be stored between 15 - 30 Celsius . 
5.5 Preparation and Packaging  
For details regarding the prepar ation and packaging, see Appendix A 
5.6 Administration and Accountability   
Study product will be labeled, dispensed, and stored by IDS.  After the baseline FDG -PET/CT scan has 
been revi ewed, patients will receive a 28 -day supply of the study medication (apremilast) and instructed 
to take oral tablets daily according to the initial titration schedule .  At subsequent visits, they will receive 
pill bottles with a 30 day supply (60 pills) and will continue twice daily dosi ng. (see section 1.3) .  
Packages of study product will be shipped from IDS to study sites outside of the University of 
Pennsylvania (Penn).  The process for study drug dispensing and return at these sub -sites will conducted 
using a similar approach as Penn.   
 
Penn IDS will perform ongoing product reconciliation for all study sites by tracking and verifying shipment 
dates, dispensing dates and amounts, administration dates and amounts, local product inventory, and 
return or destruction of unused product.    
 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  18 
5.7 Subject Compliance Monitoring  
During monthly study visits, patient s will be asked to bring the empty blister packs  or pill bottles , with any 
remaining medication .  The number of pills remaining will be noted and the patient will be provided with 
an additional  30-day supply.  
5.8 Return or Destruction of Investigational Product  
Unused study drugs will be destroyed with signed documentation of drug administration sent to the IDS. 
At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, drug 
destroyed, and drug remaining. This reconciliation  will be logged on the drug reconciliation form, signed, 
and dated. Any discrepancies noted will be investigated, resolved, and documented prior to destruction of 
unused study drug.  
6 Study Procedures  
The study procedures for each visit are summarized in the Appendix C.  
6.1 Screening (Day -30 to Day -1) 
 Sign informed consent  
 Review of inclusion and exclusion criteria  
 Record demographic information (i.e., sex, date of birth, race/ethnicity, etc.)  
 Record height and weight  
 Record vital signs, including temperature, pulse, respiratory rate and blood pressure  
 Medical and surgical history including date of onset of psoriasis and documentation of history of 
psoriatic arthritis , including specialty of diagnosing physician  
 Social history, including alcohol, to bacco, and other recreational drug use  
 Review of systems  
 Physical exam  
 % BSA assessment  
 PASI and PGA score  
 Laboratory evaluation  for safety  (within 30 days of baseline visit)  
o Hematology: CBC with differential  
o Complete Metabolic Profile : sodium, potassium,  chloride, bicarbonate, BUN, creatinine, 
glucose,  aspartate aminotrans ferase , alanine aminotrans ferase , alkaline phosphatase, 
total and direct bilirubin, total protein, albumin  
o HIV, hepatitis b surface antigen , hepatitis C antibody  
o Urine  pregnancy test for women of childbearing potential (includes women who have had 
a tubal ligation)  
 Review and document medications or therapies and any discontinued medications or therapies in 
the last 90 days  
 Review and document all prior and current psor iasis medications or therapies, including duration 
of therapy, and if applicable, when and why therapy was discontinued  
6.2 Study Intervention Phase  
6.2.1  Visit 1  / Baseline Visit  (Day 0 )  
 Review of inclusion and exclusion criteria  
 Review and update of medical histo ry for any interim events between screening and baseline  
 Review and update of any changes in medications/therapies between screening and baseline  
 Monitor concomitant psoriasis therapy  
 Monitor alcohol and tobacco use  
 Review of systems  
 Vital signs, weight  
 Physical exam ,  
 % BSA assessment  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  19 
 PASI and PGA score  
 DLQI  
 Pruritus VAS  
 Urine pregnancy test for women of childbearing potential (includes women who have had a tubal 
ligation)  
 FDG -PET/CT scan prior to treatment initiation  
 Collection of blood samples for  cardiometabolic biomarkers prior to treatment initiation   
 Review of clinical findings on FDG -PET/CT  
 Review and evaluation of any adverse events or serious adverse events  
 Dispense a 28-day supply of apremilast within 7 days of FDG -PET/CT , if no medical 
contraindications are identified on PET/CT  
6.2.2  Visit 2  / Week 4 Visit  (Day 28 +/ - 7 days)  
 Review and evaluation of any adverse events or serious adverse events  
 Monitor concomitant psoriasis therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam, if indicated by patient report of adverse events  
 % BSA assessment  
 PASI and PGA score  
 Collection of blood for  cardiometabolic biomarkers  
 Collect  remaining pills and dispense a 30-day supply of apremilast   
6.2.3  Visit 3  / Week 8 Visit  (Day 56 +/- 7 days)  
 Review and evaluation of any adverse events or serious adverse events  
 Monitor concomitant psoriasis therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam if indicated by patient report of adverse events  
 % BSA assessment  
 PASI and PGA score  
 Collection of blood sa mples for  cardiometabolic biomarkers  
 Collect remaining pills and dispense a 30 -day supply of apremilast   
 
6.2.4  Visit 4 / Week 12 Visit (Day 84 +/ - 7 days)  
 Review and evaluation of any adverse events or serious adverse events  
 Monitor concomitant psoriasis therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam if indicated by patient report of adverse events  
 % BSA assessment  
 PASI and PGA score  
 Collection  of blood samples for  cardiometabolic biomarkers  
 Collect  remaining pills and dispense a 30-day supply  of apremilast  
6.2.5  Visit 5  / Week 16 Visit  (Day 112 +/ - 7 days)  
 Review and evaluation of any adverse events or serious adverse events  
 Monitor concomitant psoriasis therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam   
 % BSA assessment  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  20 
 PASI and PGA score  
 DLQI  
 Pruritus VAS  
 Laboratory evaluation  for safety  
o Hematology: CBC with differential  
o Complete Metabolic Profile: sodium, potassium, chloride, bicarbonate, BUN, creatinine, 
glucose,  aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase, 
total and direct bilirubin, total protein, albumin  
o Urine  pregnancy test for women of childbearing potential (includes women who have had 
a tubal ligation)  
 Collection  of blood samples for  cardiometabolic biomarkers  
 FDG -PET/CT scan  
 Collect  remaining pills and dispense a 30-day supply of apremilast   
6.2.6  Visit 6 / Week 28 Visit  (Day 196 +/- 7 days)  
 Review and evaluation of any adverse events or serious adverse events  
 Monitor concomitant psoriasis therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam if indicated by patient report of adverse events  
 % BSA assessment  
 PASI and PGA score  
 Collect remaining pills and dispense a 30 -day supply of apremilast  
6.2.7  Visit 7 / Week 40 Visit  (Day 280 +/- 7 days)  
 Review and evaluation of any adverse events o r serious adverse events  
 Monitor concomitant psoriasis therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam if indicated by patient report of adverse events  
 % BSA assessment  
 PASI and PGA score  
 Collect remaining pills and dispense a 30 -day supply of apremilast  
6.2.8  Visit 8 / Week 52/EOS Visit  (Day 364 +/- 7 days)  
 Review and evaluation of any adverse events or serious adverse events  
 Monitor concomitant psoriasis therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam  
 % BSA assessment  
 PASI and PGA score  
 DLQI  
 Pruritus VAS  
 Laboratory evaluation for safety  
o Hematology: CBC with differential  
o Complete Metabolic Profile: sodium, potassium, chloride, bicarbonate, BUN, creatinine, 
glucose, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatas e, 
total and direct bilirubin, total protein, albumin  
o Urine pregnancy test for women of childbearing potential (includes women who have had 
a tubal ligation)  
 Collection  of  blood for cardiometabolic biomarkers  
 FDG -PET/CT scan  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  21 
 Collect remaining pills  
6.3 Unsch eduled Visits  
 Review and evaluation of any adverse events or serious adverse events  
 Monitor concomitant therapy  
 Review of systems, if indicated  
 Vital signs, weight  
 Physical exam, if indicated  
 Laboratory evaluation, if indicated by patient symptoms and deemed appropriate by  investigator  
6.4 Subject Withdrawal  
Subjects may withdraw from the study at any time  without impact to their care. They may also be 
discontinued from the study at the discretion of the Investigator for lack of adherence to intervention or 
study proced ures or visit schedules, or AEs . The Investigator may also withdraw subjects who violate the 
study plan, or to protect the subject for reasons of safety or for administrative reasons.  It will be 
documented whether or not each subject comple tes the clinical study. Subjects who withdraw early will 
have one final visit to collect the remaining study drug, follow up regarding adverse events and undergo 
clinical, laboratory and imaging assessment as desc ribed below in section 6. 5. 
6.5 Early Terminati on Visits   
 Review and evaluation of any adverse events or serious adverse events  
 Monitor psoriasis concomitant therapy  
 Review of systems  
 Vital signs, weight  
 Physical exam  
 % BSA assessment  
 PASI and PGA score  
 DLQI  
 Pruritus VAS  
 Laboratory evaluation  for safety , at the discretio n of the investigator  
o Hematology: CBC with differential  
o Complete Metabolic Profile: sodium, potassium, chloride, bicarbonate, BUN, creatinine, 
glucose,  aspartate aminotrans ferase, alanine aminotrans ferase , alkaline phosphatase, 
total and direct bilirubin, total protein, albumin  
o Urine  pregnancy test for women of childbearing potential (includes women who have had 
a tubal ligation)  
 FDG -PET/CT scan, if  previous  FDG -PET/CT scan (baseline and/or Week 16) was performed 
more than 28 days ago , or at the discretion of the investigator  
 Collection of blood  for cardiometabolic biomarkers , if last labs wer e drawn more than 28 days 
ago, or at the discretion of the investigator  
7 Statistical Plan  
7.1 Primary Endpoint  
 
The primary endpoints to be measured in this study include:  
 Change in total vascular inflammation of the  whole  aorta as assessed on FDG -PET/CT between 
baseline and week 16  
 Change in cardiometabolic biomarkers  between baseline and week 16    
7.2 Secondary Endpoints  
The s econdary e ndpoints to be measured in the study include:  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  22 
 Change in total vascular inflammation of the five aortic segments  as assessed on FDG -PET/ CT 
between baseline and week 16, and between baseline and week 52   
 Change in cardiometabolic biomarkers at week 4, 8, 12 , 16 and 52 compared to baseline and 
earlier time points  
 Change in total vascular inflammation of the aorta as assessed on FDG -PET/CT between week 
52 and earlier time points (baseline and week 16)  
 Changes in body composition as measured on FDG -PET/CT between week 52 and earlier time 
points (baseline and week 16)  
 Changes in physician reported outcomes (PASI, PGA)  
 Changes in the patient reported outcomes  (DLQI , pruritus VAS ) 
 Safety endpoints  
 
7.3 Sample Size and Power Determination  
The sample size is based on primary and secondary outcome of changes in tissue -to-background ratio 
(TBR) of the standardized uptake values (SUV) of the tracer measured by FDG -PET/CT.  Using a two 
sided test with alpha=0.05 and prior standard deviation (SD) estimate of the change in TBR (SD=0.263), 
35 patients will provide 90% power to detect a clinically significant change of 0. 15 TBR between pre and 
post treatment measurements.  The 3 5 patients will also provide 90% power to detect clinically relevant 
differences in biomarkers between pre- and post -treatment  of approximately 0. 57 SD, well below the 
general threshold for significance of one SD.  To accommodate potential dropout of up to 50% at 52 
weeks , we intend to accrue 70 patients.  However, at 16 weeks w e assume our dropout rate will only be 
20%.  Assuming 56 patients will have a FDG -PET/CT at 16 weeks, we will have 98.7% power to detect 
the 0.15 change in TBR as discussed above.  
7.4 Statistical Methods  
Stata 14 .0 or a more current version (StataCorp, College Station, TX) will be used for all analyses. All data 
will be summarized using descriptive statistics (mean, SD, range for continuous variables; frequencies for 
categorical variables) and graphical techniques  (histograms, scatterplots). Tables will be produced 
describing any missing data patterns due to either withdrawal or other reasons.   
 
Primary Analysis  
The primary analysis will consist of  comparisons of total vascular inflammation of the aorta  and 
cardi ometabolic biomarkers  between week 16 and baseline  using the endpoints of change as defined in 
Section 3.2 .  Statistical significance of the change from baseline to 16 week will be assessed using a one 
sample t -test, and the use of a mixed linear model wil l also be considered .  Because the primary outcome 
is a change score, the analysis will be restricted to subjects who have completed both the baseline and 
week 16  FDG -PET/CT scan s, regardless of their level of adherence to apremilast .   
 
Secondary Analysis  
Secondary analyses will include comparisons in total vascular inflammation of the aorta  and its five 
segments , change in cardiometabolic biomarkers and change in body composition between week s 52,  16 
and at baseline. We will also perform multiple imputation to address possible sensitivity to missing data.  
Additional analyses will also include longitudinal models of psoriasis activity over time, using repeated -
measures approaches to accommodate the correla tion within subjects over time.  We will expl ore the use 
of random effects models as well .  The linear trend  between change s in TBR and psoriasis will be analyzed 
using multivariable linear regression with TBR as the dependent variable, and covariates in the model being 
age, sex, major cardiovascular  disease risk factors . 
7.4.1  Baseline Data  
Baseline and demographic characteristics will be summarized by standard descriptive statistics, including 
mean and standard deviation for continuous variables such as age and standard percentages for 
categorical variabl es such as sex . 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  23 
7.4.2  Safety Analysis  
Subjects will be monitore d for any adverse event that  occur during the study treatment period. Laboratory 
evaluation for safety will be completed at baseline , week 16  and week 52 .  
7.5 Subject Population(s) for Analysis  
Primary  analyses will be conducted according to the intention -to-treat principle, including all people who 
enrolled in the study and completed an FDG -PET/CT scan at week 16 regardless of their level of 
adherence to apremilast . Additional analyses will be conducte d in patients who were at least 90% 
adherent with apremilast dosing . 
8 Safety and Adverse Events  
8.1 Definitions   
8.1.1  Adverse Event  
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence occurring at any 
dose that may appear or worsen in a subject during the course of a study. It may be a new intercurrent 
illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject’s health, 
including laboratory test values (as specified by the criteria below), regardless  of etiology. Any medical 
condition that was present prior to study treatment and that remains unchanged or improved should not 
be recorded as an AE. If there is a worsening of that medical condition , this should be considered an AE. 
A diagnosis or syndrom e should be recorded on the AE page of the Case Report Form rather than the 
individual signs or symptoms of the diagnosis or syndrome.   All AEs will be recorded by the 
Investigator(s) from the time of signing the informed consent through the end of the des ignated follow -up 
period.  
 
Abnormal laboratory values defined as adverse events:  
An abnormal laboratory value is considered to be an AE  if the laboratory abnormality is characterized by 
any of the following:  
 Results in discontinuation from the study.  
 Requires treatment, modification/interruption of study drug dose, or any other therapeutic 
intervention.  
 Is judged by the Investigator(s) to be of significant clinical importance.  
 
If a laboratory abnormality is one component of a diagnosis or syndrome, th en only the diagnosis or 
syndrome should be recorded on the AE page of the CRF. If the abnormality was not a part of a diagnosis 
or syndrome, then the laboratory abnormality should be recorded as the AE.  
8.1.2  Serious Adverse Event  
A serious adverse event (SAE) is any AE which:  
 Results in death  
 Is life -threatening (i.e., in the opinion of the Investigator(s) the subject is at immediate risk of 
death from the AE)  
 Requires inpatient hospitalization or prolongation of existing hospitalization  
 Results in persistent o r significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions)  
 Is a congenital anomaly/birth defect  
 Constitutes an important medical event  
 
Important medical events are defined as those occurrences that may not be immediately life threatening 
or result in death, hospitalization, or disability, but may jeopardize the subject or require medical or 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  24 
surgical intervention to prevent one of the other outcomes listed above.  Medical and scientific judgment 
should be exercised in deciding whether such an AE should be considered serious.  
 
Events not considered to be SAEs are hospitalizations which: were planned before entry into the clinical 
study; are for elective treatment of a condition unrelated to the stu died indication or its treatment; occur 
on an emergency outpatient basis and do not result in admission (unless fulfilling other criteria above); 
are part of the normal treatment or monitoring of the studied indication and are not associated with any 
deter ioration in condition.  
 
If an AE is considered serious, both the AE pages of the CRF and the SAE Report Form must be 
completed.  
 
For each SAE, the Investigator(s) will provide information on severity, start and stop dates, relationship to 
study drug, actio n taken regarding study drug, and outcome.  
8.2 Recording of Adverse Events  
For each subject, AEs and SAEs occurring after informed consent is obtained should be recorded until 
the subject has completed his/her participation in the study. A serious adverse event must be reported if it 
occurs during a subject’s participation in the  study and/or within 30 days of receiving the last dose of the 
study drug.  
 
Any serious adverse event that is ongoing when a subject completes his/her participation in the Study 
must be followed until any of the following occurs:  
 The event resolves or stabilizes;  
 The event returns to baseline condition or value (if a baseline value is available);  
 The event can be attributed to agents(s) other than the Study Product, or to factors unrelated to 
Study conduct.  
 
Any subsequent AE felt to be causally related  to the use of the study product should be reported.  
8.3 Relationship of AE to Study  
The Investigator(s) must determine the relationship between the administration of study drug and the 
occurrence of an AE/SAE as not suspected or suspected as defined below:  
 
Not suspected : The temporal relationship of the adverse event to study drug 
administration makes a causal relationship unlikely or remote , or 
other medications, therapeutic interventions, or underlying conditions 
provide a sufficient explanation for the ob served event  
 
Suspected:  The temporal relationship of the adverse event to study drug 
administration makes a causal relationship possible,  and other 
medications, therapeutic interventions, or underlying conditions do not 
provide a sufficient explanation f or the observed event.  
 
8.4 Reporting of Adverse Events, Adverse Device Effects and Unanticipated Problems  
Immediate reporting of serious adverse events:  
Any AE that meets any criterion for a SAE requires the completion of an SAE Report Form in addition to 
being recorded on the AE pages of the CRF.  The Investigator(s) is required to ensure that the data on 
these forms is accurate and consistent.  This appl ies to all SAEs, regardless of relationship to study drug, 
that occur after informed consent has been obtained , those made known to the Investigator(s) within 30 
days after a subject’s last dose of study drug, and those made known to the investigator(s) at  any time  
that are suspected of being related to study drug.  
 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  25 
Investigators who are not Penn faculty or affiliated with a Penn research site are responsible for reporting 
consistent with timeframes and guidance here as well as consistent with their local I RB requirements.   
 
The SAE must be reported immediately (i.e., within 24 hours of the Principal Investigators’ knowledge of 
the event) to Amgen  Safety by facsimile  (see below for contact information) .  A w ritten report, prepared by 
the sub-site Investigator or Penn Principal Investigator(s) using an SAE Report Form or a 3500A 
Medwatch form , is to be faxed to Amgen  Safety (see below for contact information).   
 
The SAE report should provide a detailed description of the SAE.  If a subject has died and an autopsy 
has been performed, copies of the autopsy report and death certificate are to be sent to Amgen  as soon 
as these become available.  Any follow -up data will be detailed in a subsequent SAE Report Form or 
Medwatch form and sent to Amgen  Safety. 
 
The Investigator(s) is responsible for informing the Institutional Review Board/Ethics Committee (IRB/IEC) 
of the SAE and providing them with all relevant initial and follow -up information about the event. The 
Investigator(s) must keep copies of all SAE in formation, including correspondence with Amgen  and the 
IRB/IEC, on file.  All SAEs that have not resolved upon discontinuation of the subject’s participation in the 
study must be followed until either the event resolves completely, stabilizes/resolves with  sequelae, or 
returns to baseline (if a baseline value is available).  
 
Pregnancies :  
When a female subject of childbearing potential’s contraceptive measures or ability to become pregnant 
changes at the time of study entry or at any time during the study, the Investigator will educate the subject 
regarding options and correct and consistent use of effective contraceptive methods in order to 
successfully prevent pregnancy.  
 
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless  of age or 
disease state) of a female subject or the female partner of a male subject  occurring while the subject is on 
study drug, or within 30 days of the subject’s last dose of study drug, are considered immediately 
reportable events.  Study drug is to be discontinued immediately and the subject instructed to return any 
unused portion of the study drug to the investigator(s).  The pregnancy, suspected pregnancy, or positive 
pregnancy test must be reported to Amgen  Safety immediately facsimile (see below for contact 
information ) using the Pregnancy Report form provided by Amgen . 
 
The female should be referred to an obstetrician -gynecologist experienced in reproductive toxicity for 
further evaluation and counseling.  
 
The Investigator(s) will follow the fema le subject until completion of the pregnancy, and must notify 
Amgen  Safety of the outcome of the pregnancy as a follow -up on the follow up Pregnancy Reporting 
form.  
 
If the outcome of the pregnancy meets the criteria for immediate classification as a SAE ( i.e., 
spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to be 
documented], stillbirth, neonatal death, or congenital anomaly [including that in an aborted fetus]), the 
Investigator(s) should follow the procedures f or reporting SAEs (i.e., report the event to Amgen  Safety by 
facsimile within 24 hours of the Investigator’s knowledge of the event).  In the case of a live “normal” birth, 
Amgen  Safety should be advised by facsimile within 24 hours of the Investigator’s knowledge of the 
event.  
 
All neonatal deaths that occur within 30 days of birth should be reported, without regard to causality, as 
SAEs.  In addition, any infant death after 30 d ays that the Investigator(s) suspects is related to the in 
utero exposure to the study drug should also be reported to Amgen  Safety by facsimile within 24 hours of 
the Investigators’ knowledge of the event.  
 
If the female is found not to be pregnant, any d etermination regarding the subject’s continued 
participation in the study will be determined by the Investigator(s) and the Amgen  Medical Monitor.  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  26 
 
Overdose : 
Abuse, withdrawal, sensitivity, or toxicity to an investigational product should be reported as an  
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be  
reported as an AE.  Any sequela of an accidental or intentional overdose of an investigational product 
should be reported as an AE.  
 
If the sequela of an overdos e is an SAE, then the sequela must be reported on  
an SAE report form. The overdose resulting in the SAE should be identified as the cause of the event on 
the SAE report form but should not be reported as an SAE itself.  
 
In the event of an overdose, the sub ject should be monitored as appropriate and should receive  
supportive measures as necessary. There is no known specific antidote for apremilast overdose.  
Actual treatment should depend on the severity of the clinical situation and the judgment and  
experien ce of the treating physician.  
 
Overdose for this protocol, on a per dose basis, is defined as ingestion of any more than the amount 
prescribed of apremilast tablets in any 24 hour period whether by accident or intentionally.  
 
8.4.1  Follow -up report  
If an SAE has not resolved at the time of the initial report and new information arises that changes the 
investigator’s assessment of the event, a follow -up report including all relevant new or reassessed 
information (e.g., concomitant medication, medical history) s hould be submitted to  Amgen  Safety and the  
IRB. The investigator is responsible for ensuring that all SAE s are followed until either resolved or stable.  
8.4.2  Investigator reporting: notifying Amgen  
 
 Amgen should receive copies of all safety reports submitted to the FDA, or any other regulatory 
agency, IRB or IEC, within 24 hours of such submission. Such notifications should be submitted as 
E2B, MedWatch or CIOMS I reports using the enclosed ISS Safety  Fax Transmittal Cover Sheet and 
faxed to 888 -814-8653.   
  
Investigator Reporting: Notifying the Penn IRB  
The University of Pennsylvania IRB (Penn IRB) requires expedited reporting of those events related to 
study participation that are unforeseen and indicate that participants or others are at increased risk of 
harm.  The Penn IRB will not acknowledge safety reports or bulk adverse event submissions that do not 
meet the all of the following criteria : 
 Unexpected  (in terms of nature, severity or frequency) given (a)the research procedure 
described in this protocol and the informed consent document and (b) the ch aracteristics of the 
population being studied  
 Related or possibly related to participation in the research  
 Suggests that the research places subjects or other at a greater risk of harm (physical, 
psychological, economic or social harm) than was previously  known or recognized    
 
Unanticipated problems posing risks to subjects or others as noted above will be reported to the Penn 
IRB via the HS -ERA online system (including a description of the event with information regarding its 
fulfillment of the above cr iteria, follow -up/resolution and need for revision to consent form and/or other 
study documentation)  within 10 working days from the time the Investigator becomes aware of the event.   
Copies of each report and documentation of IRB notification and receipt will be kept in the Clinical 
Investigator’s study file.  
 
Reporting Deaths :   
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  27 
Concerning deaths that occur during the course of a research study, the following describes the more 
rapid reporting requirement of the Penn IRB for specific situations:  
 Report th e event within 24 hours  when the death is unforeseen (unexpected) and indicates 
participants or others are at increased risk of harm.  
 Report the event within 72 hours,  for all other deaths, regardless of whether the death is related to 
study participation.  
 
For reportable deaths, the initial submission to the Penn IRB may be made by contacting the IRB Director 
or Associate Director. The SAE report can follow via the HS -ERA online system.   
 
Other Reportable events:  
For clinical drug trials, the following ev ents are also reportable to the Penn IRB:  
 Any adverse experience that, even without detailed analysis, represents a serious unexpected 
adverse event that is rare in the absence of drug exposure (such as agranulocytosis, hepatic 
necrosis, Stevens -Johnson sy ndrome).  
 Any adverse event that would cause Amgen  to modify the investigators brochure, protocol or 
informed consent form, or would prompt other action by the IRB to assure protection of human 
subjects.  
 Information that indicates a change to the risks or p otential benefits of the research, in terms of 
severity or frequency. For example:  
– An interim analysis indicates that participants have a lower rate of response to treatment than 
initially expected.  
– Safety monitoring indicates that a particular side effect is more severe, or more frequent than 
initially expected.  
– A paper is published from another study that shows that an arm of your research study is of no 
therapeutic value.  
 Change in FDA safety labeling or withdrawal from marketing of a drug, device,  or biologic used in a 
research protocol.  
 Breach of confidentiality  
 Change to the protocol taken without prior IRB review to eliminate apparent immediate hazard to a 
research participant.  
 Incarceration of a participant when the research was not previously approved under Subpart C and 
the investigator believes it is in the best interest of the subject to remain on the study.  
 Complaint of a participant when the complaint indicates unexpected risks or the complaint cannot 
be resolved by the research team.  
8.5 Stop ping Rules  
Since these study treatments are FDA -approved treatments for psoriasis, standard of care for monitoring 
apremilast treatment will be used to ensure primary safety endpoints outlined in Section 3.2. Subjects will 
be monitored for adverse events and serious adverse events by the Investigators at each study visit. 
Subjects who experience adverse events may be removed from study participation at the discretion of the 
Investigator . 
8.6 Medical Monitoring  
It is the responsibility of the Principal Investig ator to oversee the safety of the study at his/her site.  This 
safety monitoring will include careful assessment and appropriate reporting of adverse events as noted 
above.  Medical monitoring will include regular assessments of the number and type of adve rse and 
serious adverse events as well as implementation of a Data and Sa fety Monitoring Plan (Appendix F).     
8.6.1  Data and Safety Monitoring Plan  
See Appendix F. 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  28 
9 Study Administration, Data Handling and Record Keeping  
9.1 Confidentiality  
Information about study su bjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a 
signed subject authorization informing the subject of the following:  
 What p rotected health information (PHI) will be collected from subjects in this study  
 Who will have access to that information and why  
 Who will use or disclose that information  
 The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, 
retains the ability to use all information collected prior to the revocation of subject authorization.  For 
subjects that have revoked authorization  to collect or use PHI, attempts should be made to obtain 
permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study 
period.  
 
The study will  take the following precautionary measures to protect subjects’  privacy and the 
confidentiality of research and/or medical records. Research records are kept in offices that are locked, 
only accessible by study staff.   Computerized records are entered only with subject ID, are kept in 
databases on institution ally secure servers and managed network drives maintained and backed -up on a 
regular basis, protected using firewall technologies, and restricted  to individuals authorized to work on the 
study  with regular monitoring for unauthorized access and other poten tial security and operational events .  
External laboratories that will analyze biologic samples from this study will not receive information that 
could identify the subject. These laboratories will only receive a number to identify the samples. It is a 
requirement that subjects involvement in the study be noted in his/her medical records. Medical records 
also include electronic medical records or EMR. If a subject ’s primary care physician is different from the 
study doctor for this study, he/she may also be  notified. Medical records may also be reviewed and 
copies made by members of either the institutional review board/independent ethics committee 
responsible for this trial site, or a regulatory agency. These individuals will see subjects name, other 
person al information such as date of birth and gender, and medical information, but shall not disclose this 
information to anyone else. At the conclusion of the data collection phase of the study, de -identified data 
sets will be prepared for analyses purposes.  Only the study data manager will retain the ability to re -
identify data, if needed for AE reporting or medical monitoring.  
9.2 Data Collection and Management  
Designated investigator staff will enter the data required by the protocol into the  Electronic Case R eport 
Forms (CRF ) using fully validated software that conforms to US 21 CFR Part 11 requirements.  
Automatic validation programs check for data discrepancies and, by generating appropriate error 
messages, allow the data to be confirmed or corrected online by the designated investigator site staff. 
The Investigator must certify via electronic approval th at the data entered into the CRFs are complete and 
accurate. After database lock, the Investigator will receive copies of the subject data for archiving at t he 
investigational site.  
 The Investigator must maintain source documents for each subject in the study .  Source data is 
all information, original records of clinical findings, observations, or other activities in a clinical trial 
necessary for the recons truction and evaluation of the trial.  Source data are contained in source 
documents.  Examples of these original documents, and data records include: hospital records, clinical 
and office charts, laboratory notes, memoranda, subjects’ diaries or evaluatio n checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcriptions certified after 
verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic 
media, x -rays, subject fil es, and records kept at the pharmacy, at the laboratories, and at medico -
technical departments involved in the clinical trial.  
 Electronic study case report form (CRF) is the primary data collection instrument for the study.  If 
data is recorded directly o n the CRF (i.e. no prior written or electronic record of data), the CRF is to be 
considered the source data (per ICH GCP Section 6.4.9).  All data requested on the CRF must be 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  29 
recorded.  All missing data must be explained.  If any entry error has been made , all correction changes 
must be initialed and dated. For clarification of illegible or uncertain entries, the clarification must be 
initialed and dated.  
 The Investigator must also keep the original informed consent form signed by the subject (A 
signed co py is given to the subject).  
9.3 Records Retention  
It is the investigator’s responsibility to retain study essential documents for at least 2 years after the final 
study results are presented in a public forum.   These documents should be retained for a longer  period if 
required by an agreement with Amgen .  In such an instance, it is the responsibility of Amgen  to inform the 
investigator/institution as to when these documents no longer need to be retained.  
10 Study Monitoring, Auditing, and Inspecting  
10.1 Auditing and  Inspecting  
The Investigator will permit study -related monitoring, audits, and inspections by the EC/IRB, Amgen , 
government regulatory bodies, and University compliance and quality assurance groups of all study 
related documents (e.g. source documents, reg ulatory documents, data collection instruments, study data 
etc.). The Investigator will ensure the capability for inspections of applicable study -related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.).  
 
Participation as an Investigator in this stu dy implies acceptance of potential inspection by government 
regulatory authorities and applicable University compliance and quality assurance offices.  
11 Ethical Considerations  
This study is to be conducted according to US and international standards of Good Clinical Practice (FDA 
Title 21 part 312 and International Conference on Harmonization guidelines), applicable government 
regulations and Institutional research policies and procedures.  
 
This protocol and any amendments will be submitted to a properly cons tituted i ndependent Ethics 
Committee  (EC) or Institutional Review Board (IRB), in agreement with local legal prescriptions, for formal 
approval of the study conduct.  The decision of the EC/IRB concerning the conduct of the study will be 
made in writing to  the investigator and a copy of this decision will be provided to Amgen  before 
commencement of this study.  The investigator should keep  a list of EC/IRB members and their affiliate 
on file . 
 
All subjects for this study will be provided a consent form describing this study and providing sufficient 
information for subjects to make an informed decision about their participatio n in this study.  (See 
Appendix B for a copy of the Subject Informed Consent Form. ) This consent form will be submitted with 
the pr otocol for review and approva l by the EC/IRB for the study. The formal consent of a subject, using 
the EC/IRB -approved consent form, must be obtained before that subject undergoes any study 
procedure.  The consent form must be signed by the subject or lega lly acceptable surrogate, and the 
investigator -designated research professional obtaining the consent.   
11.1 Risks  
Apremilast is a  FDA-approved , first-line treatment for psoriasis with very low risk of serious side effects 
with short -term exposure and minimized  by careful adherence to FDA prescribing guidance and strict 
exclusion of subjects with significant contraindications to the medication. Subjects will undergo regular 
medical monitoring for any adverse reactions.  
 
Potential risks from the study assessment procedures are low. Exposure to radiation from this study is not 
significant and is within the acceptable range for research studies involving the administration of 
radiopharmaceuticals and use of CT as outlined by  the regulatory agencies. This radiation dose is not 
necessary for medical care and will occur only as a result of subject participation in the study.  At doses 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  30 
much higher than the subject will receive in this study, radiation is known to increase the ris k of 
developing cancer after many years. At the doses of radiation subjects will receive in this study, it is very 
likely that no effects will be seen . There is a risk of allergic or other adverse type reaction to FDG but this 
is extremely rare.  Phlebotomy  required for cardiometabolic assessments is potentially associated with 
pain, bruising, bleeding, vasovagal syncope , thrombosis, and, rarely, infection at the venipuncture site.   
11.2 Benefits  
Direct Benefits : Potential benefits for study participation include comprehensive laboratory safety tests  
and FDG -PET/CT assessment at no cost, the results of which will be reviewed with each subject and that 
can be brought to each subject’s medical provider(s) for optim ization and management of their CV risk. 
Subjects will receive apremilast, an FDA -approved psoriasis treatment with substantial efficacy and 
established safety profile, at no cost for 52 weeks.  
 
Indirect Benefits:  Data derived from this study will provide  critical information on the impact of apremilast 
on vascular inflammation cardiometabolic function  and body composition . 
11.3 Risk Benefit Assessment  
Overall, we expect that the risks of the research study are outweighed by the potential benefits to the 
partic ipants and others .   
11.4 Informed Consent Process / HIPAA Authorization  
Eligible subjects may only be included in the study after providing written (witnessed, where required by 
law or regulation), IRB/IEC -approved informed consent, or, if incapable of doing so, after such consent 
has been provided by a legally acceptable representative(s) of the subject. In cases where the subject’s 
representative gives consent, the subject should be informed about the study to the extent possible given 
his/her understanding.  If the subject is capable of doing so, he/she should indicate assent by personally 
signing and dating the written informed consent document or a separate assent form. Informed consent 
must be obtained before conducting any study -specific procedures (i.e.,  all of the procedures described in 
the protocol). The process of obtaining informed consent should be documented in the subject source 
documents . 
12 Study Finances  
12.1 Funding Source  
The study is financed through a grant from Amgen  Corporation .  
12.2 Conflict of Interest  
Any investigator who has a conflict of interest with this study (patent ownership, royalties, or financial gain 
greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by a properly 
constituted Conflict of In terest Committee with a Committee -sanctioned conflict management plan that 
has been reviewed and approved by the institution  prior to participation in this study.  All University of 
Pennsylvania investigators will follow the University conflict of interest  policy . 
12.3 Subject Stipends or Payments  
Subjects will be asked to commute to study sites at 4 week intervals for monitoring visits and to receive 
the study drug. Visits that involve laboratory evaluation without FDG -PET/CT scan are estimated to take 
up to tw o hours. Visits that involve FED -PET/CT scan are estimated to take up to 6 hours.  
 
For each study visit , including the screening visit, subjects will be reimbursed $3 0 to offset travel and 
other indirect costs for study participation. For visits including an FDG -PET/C T scan subjects will receive 
$150 per visit.  Additional assistance for travel -related expenses  may be available. In the event  additional 
assistance is made available, the costs would have to be paid for by the participant up front and would be  
reimbursed by the study as set forth by the study team. When the subject has reached the end of study 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  31 
participation, after the last study visit, the subject will receive a check in the mail with the total amount to 
be reimbursed for all study visits , minu s any amount they have already received for their travel and/or 
related costs associated with travel to study visits . If the subject does not complete all study visits the 
amount received will be pro -rated to reflect the number and type of visits completed . Subjects will need to 
complete a W -9 form which is required by the IRS when study participation will result in a subject 
receiving more than $600 in a calendar year. This form will be provided for subjects.  
13 Publication Plan  
Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the 
information provided by Amgen  and University of Penn sylvania  for the purposes of performing the study, 
will be published or passed on to any third  party without the consent of the study principal investigator  
and Amgen .  Any investigator involved with this study is obligated to provide Amgen  with complete test 
results and all data derived from the study.  
14 References  
1. Gelfand JM, Wang X, Qing L, et al. Epidemiology and Treatment Patterns of Psoriasis in the General 
Practice Research Database (GPRD). Pharmacoepidemiology and drug safety. 2005;14:S23.  
2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagn osed psoriasis in US adults: 
results from NHANES 2003 -2004. Journal of the American Academy of Dermatology. Feb 2009;60(2):218 -
224. 
3. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden 
even when not ext ensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol 
Symp Proc. Mar 2004;9(2):136 -139. National Psoriasis Foundation. Statistics.  
http://www.psorias is.org/netcommunity/learn_statistics . . Accessed November 4, 2009.  
4. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results 
of National Psoriasis Foundation survey. Journal of the American Academy of Dermatol ogy. Dec 
2007;57(6):957 -962. 
5. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: 
atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. Jul 2009;161(1):1 -7. 
6. Qureshi AA, Choi HK, Setty AR, Curhan G C. Psoriasis and the risk of diabetes and hypertension: a 
prospective study of US female nurses. Archives of dermatology. Apr 2009;145(4):379 -382. 
7. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population -based 
study. Br J Dermatol. Dec 2008;159(6):1331 -1337.  
8. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population -based cross -sectional study. 
Journal of the European Academy of Dermatology and Venereology : JEADV. May 2008;22(5):585 -589. 
9. Solomon DH , Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid 
arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis. Dec 2010;69(12):2114 -2117.  
10. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in 
women: Nurses' Health Study II. Archives of internal medicine. Aug 13 -27 2007;167(15):1670 -1675.  
11. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is  associated with lipid abnormalities at the onset of 
skin disease. Journal of the American Academy of Dermatology. Apr 2006;54(4):614 -621. 
12. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular 
risk: a  Danish nationwide cohort study. J Intern Med. Oct 29 2010.  
13. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in 
patients with psoriasis. JAMA : the journal of the American Medical Association. Oct 11 2006;296(1 4):1735 -
1741.  
14. Lin HW, Wang KH, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5 -year 
population -based study in Taiwan. J Am Acad Dermatol. Mar 2011;64(3):495 -501. 
15. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and r isk of incident myocardial infarction, stroke or 
transient ischaemic attack: an inception cohort study with a nested case -control analysis. The British journal 
of dermatology. May 2009;160(5):1048 -1056.  
16. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. The Journal of 
investigative dermatology. Oct 2009;129(10):2411 -2418.  
17. Kimball AB, Guerin A, Latremouille -Viau D, et al. Coronary heart disease and stroke risk in patients with 
psoriasis: retrospective analysis. Am J Med. Apr 2010;123(4):350 -357. 
18. Ahlehoff O, Gislason GH, Lindhardsen J, et al. Prognosis following first -time myocardial infarction in patients 
with psoriasis: a Danish nationwide cohort study. J Intern Med. Mar 1 2011.  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  32 
19. Mehta NN, Azfar RS, Shin DB, Neimann AL, Tr oxel AB, Gelfand JM. Patients with severe psoriasis are at 
increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur 
Heart J. Apr 2010;31(8):1000 -1006.  
20. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN -gamma, IL -6, IL-8, IL-12, IL -17, and 
IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. Oct 24 
2005;2005(5):273 -279. 
21. Krueger JG. The immunologic basis for the treatment of psoriasis with new bio logic agents. Journal of the 
American Academy of Dermatology. Jan 2002;46(1):1 -23; quiz 23 -26. 
22. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Annals of the 
rheumatic diseases. Mar 2005;64 Suppl 2:ii30 -36. 
23. Lowes MA, Bowc ock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. Feb 22 
2007;445(7130):866 -873. 
24. Lowes MA, Kikuchi T, Fuentes -Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of 
Th1 and Th17 T cells. The Journal of investigative dermatology. May 2008;128(5):1207 -1211.  
25. Takahashi H, Tsuji H, Hashimoto Y, Ishida -Yamamoto A, Iizuka H. Serum cytokines and growth factor levels 
in Japanese patients with psoriasis. Clinical and experimental dermatology. Aug 20 10;35(6):645 -649. 
26. Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL -22 correlates with psoriatic severity and 
serum IL -6 correlates with susceptibility to phototherapy. Journal of dermatological science. Jun 
2010;58(3):225 -227. 
27. Ridker PM. High -sensitivity C -reactive protein: potential adjunct for global risk assessment in the primary 
prevention of cardiovascular disease. Circulation. Apr 3 2001;103(13):1813 -1818.  
28. Ridker PM, Buring JE, Rifai N. Soluble P -selectin and the risk of f uture cardiovascular events. Circulation. 
Jan 30 2001;103(4):491 -495. 
29. Ridker PM, Hennekens CH, Roitman -Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble 
intercellular adhesion molecule 1 and risks of future myocardial infarction in apparentl y healthy men. Lancet. 
Jan 10 1998;351(9096):88 -92. 
30. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor -alpha 
and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(1 8):2149 -
2153.  
31. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C -reactive protein and low -density 
lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. Nov 14 
2002;347(20):1557 -1565.  
32. Ridker PM, Rifai N,  Stampfer MJ, Hennekens CH. Plasma concentration of interleukin -6 and the risk of 
future myocardial infarction among apparently healthy men. Circulation. Apr 18 2000;101(15):1767 -1772.  
33. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprote in(a) and the risk of future 
stroke. Jama. Apr 26 1995;273(16):1269 -1273.  
34. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at 
increased risk of cardiovascular mortality: cohort study using the General Pract ice Research Database. Eur 
Heart J. Dec 27 2009.  
35. Lahoute C, Herbin O, Mallat Z, Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future 
therapeutic targets. Nature reviews. Cardiology. Jun 2011;8(6):348 -358. 
36. Chen S, Crother TR, Arditi M. Emer ging role of IL -17 in atherosclerosis. Journal of innate immunity. 
2010;2(4):325 -333. 
37. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and 
cardiovascular disease. Int J Med Sci. 2010;7(5):284 -289. 
38. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England journal of 
medicine. Apr 21 2005;352(16):1685 -1695.  
39. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(12):1876 -
1890.  
40. Mehta NN, Mc Gillicuddy FC, Anderson PD, et al. Experimental Endotoxemia Induces Adipose Inflammation 
and Insulin Resistance in Humans. Diabetes. Sep 30 2009.  
41. Heffron SP, Parastatidis I, Cuchel M, et al. Inflammation induces fibrinogen nitration in experimental human 
endotoxemia. Free Radic Biol Med. Oct 15 2009;47(8):1140 -1146.  
42. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin 
Endocrinol Metab. Jun 2007;92(6):2272 -2279.  
43. Alexander ET, Vedhachalam C, Sankaranarayanan S, et al.  Influence of apolipoprotein A -I domain structure 
on macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. Feb 2011;31(2):320 -
327. 
44. Khera AV, Cuchel M, de la Llera -Moya M, et al. Cholesterol efflux capacity, high -density lipoprote in function, 
and atherosclerosis. N Engl J Med. Jan 13 2011;364(2):127 -135. 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  33 
45. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque -type 
psoriasis is accompanied by amelioration of biomarkers of cardiovascular r isk: results of a prospective 
longitudinal observational study. J Eur Acad Dermatol Venereol. Jan 17 2011.  
46. Basu S, Zaidi H, Houseni M, et al. Novel quantitative techniques for assessing regional and global function 
and structure based on modern imaging mod alities: implications for normal variation, aging and diseased 
states. Semin Nucl Med. May 2007;37(3):223 -239. 
47. Bural GG, Torigian DA, Chamroonrat W, et al. Quantitative assessment of the atherosclerotic burden of the 
aorta by combined FDG -PET and CT image analysis: a new concept. Nucl Med Biol. Nov 2006;33(8):1037 -
1043.  
48. Mehta NN, Yu Y, Saboury B, et al. Systemic and Vascular Inflammation in Patients With Moderate to Severe 
Psoriasis as Measured by [18F] -Fluorodeoxyglucose Positron Emission Tomography -Computed 
Tomography (FDG -PET/CT): A Pilot Study. Arch Dermatol. May 16 2011.  
49. Aziz K, Berger K, Claycombe K , Huang R, Patel R, Abela GS. Noninvasive detection and localization of 
vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission 
tomography. Circulation. Apr 22 2008;117(16):2061 -2070.  
50. Naik HB, Natarajan B, Stansky E , et al. Severity of Psoriasis Associates with Aortic Vascular Inflammation 
Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study.  Arterioscler 
Thromb Vasc Biol . 2015 ;ATVBAHA.115.306460.  Published  online  before  print October  8 
2015 , doi:10.1161/ATVBAHA.115.306460.  
51. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable 
cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. Mar-Apr 
2008;15(2):209 -217. 
52. Rominger A, Saam T, Wolpers S, et al. 18F -FDG PET/CT identifies patients at risk for future vascular events 
in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. Oct 2009;50(10):1611 -1620.  
53. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by 
fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. Nov 7 2006;48(9):1825 -1831.  
54. Lee SJ, On YK, Lee EJ, Choi JY, Kim BT, Lee KH. Reversal of vascu lar 18F -FDG uptake with plasma high -
density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. Aug 2008;49(8):1277 -1282.  
55. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin -12/23 
monoclonal antibod y, in patients with psoriasis: 76 -week results from a randomised, double -blind, placebo -
controlled trial (PHOENIX 1). Lancet. May 17 2008;371(9625):1665 -1674.  
56. Schafer P. Apremilast Mechanism of Action and application to psoriasis and psoriatic arthritis. Bioche m 
Pharmacol . 2012; 83: 1583 -1590 . 
57. Houslay MD, Schafer P, Zhang KYJ. Phosphodiesterase -4 as a therapeutic target. Drug Discov Today . 
2005. 10(22); 1503 -1519. .  
58. Serezani CH, Ballinger MN, Aronoff DM, et. al.  Cyclic AMP: Master regulator of immune cell function. Am J 
Respir Cell Mol Bio l. 2008;  39(2):127-132. 
59. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol.  2011; 12(3):204 -212. 
60. Moore K J, Sheedy FJ, Fisher EA. Macr ophages in atherosclerosis: a dy namic balance. Nat Rev Immunol.  
2013; 13(10): 709-721. 
61. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011; 145 (3):341-355. 
62. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, 
Day RM, Girolomoni G, Gottlieb AB. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, 
in patients with moderate -to-severe plaque p soriasis over 52 weeks: a phase III, randomized controlled trial 
(ESTEEM 2). The British Journal of Dermatology.  Dec 2015;173(6):1387 -99. 
63. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic 
systemic treatments for moderate -to-severe psoriasis: meta -analysis of randomized controlled trials. The 
British journal of dermatology. Sep 2008;159(3):5 13-526. 
64. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) --a simple practical measure for routine clinical 
use. Clinical and experimental dermatology. May 1994;19(3):210 -216. 
65. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D. Sensitivi ty of the Dermatology Life Quality 
Index to clinical change in patients with psoriasis. The British journal of dermatology. Aug 2003;149(2):318 -
322. 
66. Mehta N N, Torigian DA, Gelfand JG, et al. Quantification of atherosclerotic plaque activity and vascular 
inflammation using [18 -F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG -
PET/CT). J Vis Exp . 2012 ; 22(63):e3777.  
67. Bural GG, Torigian DA, Chamroonrat W, et al. FDG -PET is an effective imaging modality to detect and 
quantify age -related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. Mar 2008;35(3):562 -569 
68. Chen W, Bural GG, Torigian DA, Rader DJ, Alavi A.  Emerging role of FDG -PET/CT in assessing 
atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. Jan 2009;36(1):144 -151. 
69. Summers RM, Liu J, Sussman D, Swyer AJ, Rehani B, Pickhardt PJ, Choi JR, Yao J. Association Between 
Visceral Adiposity and Colorectal Polyps on CT Colongraphy. AJR Am J Roentgenol.  Jul 2012;199(1):48 -57. 
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  34 
  
  
Vascular Inflammation in Psoriasis - Apremilast (VIP -A)                                                                Page:  35 
15 Attachments  
15.1 Appendix A - Apremilast Prescribing Information  
15.2 Appendix B -  Informed Consent  
15.3 Appendix C - Study Flow Chart  
15.4 Appendix D - Dermatology Life Quality Index (DLQI)  
15.5 Appendix  E - Sample Preparation and Handling  
15.6 Appendix F - Data Safety and Management  Plan  